February 14, 2022 02:47 PM Eastern Standard Time
BERWYN, Pa.- Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Lamotrigine ODT, USP (25mg, 50mg, 100mg and 200mg) available in bottles of 30 tablets (AB rated generic equivalent of Lamictal®), and has begun commercialization activities.
Lamotrigine ODT, USP is indicated for:
- Epilepsy adjunctive therapy in patients aged 2 years and older,
- Epilepsy monotherapy in patients aged 16 years and older, and
- Maintenance of bipolar I disorder in patients treated for acute mood episodes with standard therapy.
“We are pleased to add Lamotrigine Orally Disintegrating Tablets, USP to our generics portfolio. These products bring long term value to patients and customers in our target markets.” stated Daniel Carbery, President and CEO of Amring. “We look forward to realizing the benefits of these, and other product launches and future business development activities in 2022.”
About Amring Pharmaceuticals Inc.
Amring Pharmaceuticals is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market. The company is a subsidiary of SEVER Life Sciences B.V., a global private specialty pharmaceutical company based in the Netherlands. Amring is partnered with well-established global biopharmaceutical companies, and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
About SEVER Life Sciences B.V.
SEVER Life Sciences B.V. is a global private specialty pharmaceutical holding company committed to helping people around the world live better lives. Headquartered in the Netherlands, SEVER Life Sciences B.V. unites 4 separate pharmaceutical businesses, Nordic Pharma, Amring Pharmaceuticals Inc, Izvarino Pharma, and SEVER Pharma Solutions. They cover an interesting and diverse range of pharmaceutical products, business models, markets, and capabilities. SEVER has been created to leverage this diversity to provide better access to pharmaceutical products, improve overall efficiency between these diverse businesses and create value for its shareholders.
This press release contains forward-looking statements, including, without limitation, statements related to Amring’s business developments and the implementation of Amring’s strategic initiatives. Because these statements reflect Amring’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring, and other factors that could affect Amring’s business and financial performance. Amring does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Amring Pharmaceuticals Inc.
Marina Volin, Esq.
VP, General Counsel
SEVER Life Sciences BV
Aernout de Bruijne
Director of Finance and Operations Planning
+31 6 207 18 634